Sterne Agee Sees Teva Pharmaceutical Outperformance Continuing

On Wednesday, Sterne Agee initiated coverage on shares of Teva Pharmaceutical Industries TEVA with a Neutral rating and $53 price target. Analyst Shibani Malhotra believes “strong conversion of Copaxone 20mg/ml to its 40mg/ml formulation is crucial.” The analyst credits the stocks year to date outperformance (up 25 percent) to the company “signaling its willingness to consider a ‘transformational deal.'” Shibani would prefer “to see management focus on execution of its realignment and cost-cutting strategy before embarking on any ambitious M&A.” The stock is up one percent to $50.10 in Wednesday's trading.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsShibani MalhotraSterne Agee
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!